Racial/ethnic disparities in ovarian cancer treatment and survival

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5909-5914

  Bandera, Elisa V ^a,b,c   Lee, Valerie S ^d   Rodriguez Rodriguez, Lorna ^a   Powell, C Bethan ^e   Kushi, Lawrence H ^d  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d DIVISION OF RESEARCH   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CAUCASIAN; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE ACCESS; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RACE DIFFERENCE; THERAPY DELAY; ADJUVANT CHEMOTHERAPY; ANCESTRY GROUP; COHORT ANALYSIS; ETHNIC GROUP; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; YOUNG ADULT;

EID: 85006284584     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1119     Document Type: Article

References (23)

1. American Cancer Society. Cancer facts and figures 2015. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
2. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM.Global ovarian cancer health disparities. Gynecol Oncol 2013; 129:258-64.
3. Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control 2009;20: 1139-50.
4. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
5. Bandera EV, Maskarinec G, Romieu I, John EM. Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. Adv Nutr 2015;6:803-19.
6. Bandera EV, Lee VS, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. JAMA Oncol 2015;1:737-45.
7. Ross TR, Ng D, Brown JS, Pardee R, Hornbrook MC, Hart G, et al. TheHMO researchnetwork virtual data warehouse: a public data model to support collaboration. EGEMS 2014;2: 1049.
8. Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, et al.Building a virtual cancer research organization. J Natl Cancer Inst Monogr 2005;12-25.
9. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935-7.
10. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 2003;81:21-31.
11. Nightingale G. Carboplatin dosing in overweight and obese patients: a single-center experience. J Hematol Oncol Pharm 2011;1:18-24.
12. Griggs JJ, Culakova E, Sorbero ME, van RynM, Poniewierski MS, Wolff DA, et al. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 2007;25: 277-84.
13. Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, Van Le L, et al.Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2013;129:74-80.
14. Au-Yeung G, Webb PM, DeFazio A, Fereday S, Bressel M, Mileshkin L.Impact of obesity on chemotherapy dosing for womenwith advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecol Oncol 2014;133:16-22.
15. Hershman DL, Unger JM, Barlow WE,Hutchins LF, Martino S, Osborne CK, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 2009;27:2157-62.
16. Rodriguez N, Rauh-Hain JA, ShoniM, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2012;125: 362-6.
17. Pelissier A, Bonneau C, Chereau E, de La Motte Rouge T, Fourchotte V, Darai E, et al. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2014;135: 542-6.
18. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183-203.
19. Aragones A,Hayes SL, Chen MH, Gonzalez J, Gany FM. Characterization of the Hispanic or latino population in health research: a systematic review. J Immigr Minor Health 2014;16:429-39.
20. Ibeanu OA, Diaz-Montes TP. Outcomes in ovarian cancer among hispanic women living in the United States: a population-based analysis. Patholog Res Int 2013;2013:672710.
21. Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, et al. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol 2015;136:491-7.
22. Hershman D, Weinberg M, Rosner Z, Alexis K, Tiersten A, Grann VR, et al.Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 2003;95:1545-8.
23. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 2016;66:31-42.